| P2093 | author name string | Koshiro Nishimoto | |
| | Kent Kanao | |
| | Takashi Okabe | |
| | Suguru Shirotake | |
| | Masafumi Oyama | |
| | Go Kaneko | |
| | Yuta Umezawa | |
| P2860 | cites work | Custirsen in combination with docetaxel and prednisone for patients with metastatic castration-resistant prostate cancer (SYNERGY trial): a phase 3, multicentre, open-label, randomised trial. | Q51102220 |
| | 68Ga-PSMA-PET/CT for the evaluation of liver metastases in patients with prostate cancer. | Q64912414 |
| | Phase III, randomized, placebo-controlled study of docetaxel in combination with zibotentan in patients with metastatic castration-resistant prostate cancer | Q86563090 |
| | Prostate Cancer, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology | Q91996909 |
| | (68)Ga-PSMA ligand PET/CT in patients with prostate cancer: How we review and report | Q26747480 |
| | Docetaxel and atrasentan versus docetaxel and placebo for men with advanced castration-resistant prostate cancer (SWOG S0421): a randomised phase 3 trial | Q28294857 |
| | Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer | Q29616123 |
| | Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer | Q29616218 |
| | Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3 | Q30277291 |
| | Radiographic progression with nonrising PSA in metastatic castration-resistant prostate cancer: post hoc analysis of PREVAIL. | Q33701534 |
| | Docetaxel and prednisone with or without lenalidomide in chemotherapy-naive patients with metastatic castration-resistant prostate cancer (MAINSAIL): a randomised, double-blind, placebo-controlled phase 3 trial | Q35572535 |
| | Meta-Analysis Evaluating the Impact of Site of Metastasis on Overall Survival in Men With Castration-Resistant Prostate Cancer | Q35948297 |
| | Randomized, double-blind, placebo-controlled phase III trial comparing docetaxel and prednisone with or without bevacizumab in men with metastatic castration-resistant prostate cancer: CALGB 90401. | Q36058291 |
| | Platinum-based chemotherapy for variant castrate-resistant prostate cancer | Q36977870 |
| | Updated prognostic model for predicting overall survival in first-line chemotherapy for patients with metastatic castration-resistant prostate cancer. | Q37590738 |
| | Treatment of mCRPC in the AR-axis-targeted therapy-resistant state | Q38535099 |
| | Docetaxel and dasatinib or placebo in men with metastatic castration-resistant prostate cancer (READY): a randomised, double-blind phase 3 trial | Q41082307 |
| | Aflibercept versus placebo in combination with docetaxel and prednisone for treatment of men with metastatic castration-resistant prostate cancer (VENICE): a phase 3, double-blind randomised trial. | Q44187537 |
| | A contemporary prognostic nomogram for men with hormone-refractory metastatic prostate cancer: a TAX327 study analysis | Q46920684 |
| P433 | issue | 2 | |
| P921 | main subject | docetaxel | Q420436 |
| P304 | page(s) | 819-823 | |
| P577 | publication date | 2020-04-01 | |
| P1433 | published in | Translational andrology and urology | Q27724139 |
| P1476 | title | A case of castration-resistant prostate cancer with liver metastases achieved a complete response by docetaxel chemotherapy | |
| P478 | volume | 9 | |